医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Mutsuki Takano Was Appointed as CFO at Heartseed

2020年09月15日 PM07:25
このエントリーをはてなブックマークに追加


 

TOKYO

Heartseed Inc. (hereinafter Heartseed), a Tokyo-based biotechnology company developing iPSC-derived cardiomyocyte spheroids for the treatment of heart failure (HF), today announced that Mutsuki Takano has been appointed as Chief Financial Officer of Heartseed, effective September 14, 2020.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200915005668/en/

Heartseed pipeline (Graphic: Business Wire)

Heartseed pipeline (Graphic: Business Wire)

Heartseed expects to initiate Phase 1/2 clinical trial for its lead pipeline HS-001 for HF in 2021. Heartseed is also supporting an investigator-initiated clinical trial for HF led by Keio University. Keio University announced the clinical trial plan was approved by the Ministry of Health, Labor and Welfare on August 27th, 2020.

In light of this, Heartseed has newly established the position of CFO with the aim of building a foundation for growth and further increasing corporate value by strengthening financial management and corporate governance.

Mutsuki Takano has total 16 years business experience, and joined Heartseed in August 2020. He holds a career record in bio-tech management since 2018. He successfully raised approx. Eur 50 million mainly in Promethera Biosciences, Belgium cell therapy company. Before 2018, he had been with Mitsui & Co., where he engaged in VC investment in biotech industry, new business launches, setting-up of joint ventures, and foreign company operations in multiple regions such as US, UK, Belgium, China, and other Asian countries. He is a Certified Member Analyst of SAAJ.

“Heartseed is one of the most promising global front runners with outstanding cell development technologies for treating heart failure. I am privileged to work together for the company,” said Mutsuki Takano.

About Heartseed

Heartseed Inc. was founded in 2015 to develop and commercialize cardiac regenerative medicine developed by Prof. Keiichi Fukuda and his group at the Department of Cardiology, Keio University, Tokyo. Heartseed has original technologies throughout the process of manufacturing and delivering iPSC-derived cardiac regenerative medicine, including purification, cell delivery and iPSC production, and has raised more than USD 38 million.

Company Name:

Heartseed Inc.

Established:

November 30, 2015

President:

Keiichi Fukuda

Headquarter:

Art Complex Center 302, Daikyocho 12-9, Shinjuku-ku, Tokyo, Japan

Shareholders:

Founders/Employees/Angel Bridge/Astellas Venture Management/Shibuya Corporation/

SBI Investment, JMDC, Gene Techno Science, Nissay Capital, SMBC Venture Capital

Website:

http://www.heartseed.jp/en/index.html

For more information on Heartseed, please visit http://www.heartseed.jp/en/index.html

View source version on businesswire.com: https://www.businesswire.com/news/home/20200915005668/en/

CONTACT

Kikuo Yasui, COO, Heartseed Inc.

Tel: +81-3-6380-1068

Email: kikuo.yasui@heartseed.jp

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • Seoul Viosys’ Violeds Modules Proven to Disinfect 99% of Airborne Viruses in a Recent Testing Result
  • Aurinia Announces Collaboration and Licensing Agreement with Otsuka Pharmaceutical Co., Ltd. for the Development and Commercialization of Voclosporin in Europe and Japan
  • Kaye推出适用于冷链运输市场的Kaye® Log -80℃ 疫苗温度记录器,以满足COVID-19疫苗储存和运输的要求
  • Kaye® (ケイ)は、COVID-19ワクチンの輸送・保管のニーズに応えるためにKaye® ログ -80ワクチン温度ロガーを、コールドチェーン市場向けに導入(発売)します。
  • DNP的新型非接触式透明屏幕可通过手的动作进行操作